+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Prenatal Diagnostic Testing - Overview

  • ID: 3721910
  • Report
  • Region: Global
  • 140 Pages
  • Insight Pharma Reports
1 of 3

FEATURED COMPANIES

  • Ariosa Diagnostics
  • Bioethics Programs
  • Metabolomic Diagnostics
  • Natera
  • NX PharmaGen
  • Sequenom
  • MORE
Invasive Testing, Noninvasive Testing, and Rising Maternal Screening Methods for Preeclampsia and Preterm Labor. This report discusses improvements in invasive procedures (karyotyping vs. cytogenetics), and the rise of noninvasive screening methods and their impact on prenatal healthcare. Although covering standard invasive procedure, this report focuses on the noninvasive technologies either on the market or in development.

Highlighting noninvasive methods, several companies have come out with novel technologies that allow them to analyze fetal DNA without risk of injury to the mother or fetus. Amniocentesis and chorionic villus sampling are common methods used to analyze fetal DNA for aneuploidies but at the risk of miscarriage and infection. With noninvasive procedures, screening can be done for common aneuploidies and further analysis can be done on women with only positive results. This not only decreases the amount of unnecessary invasive testing but also the amount of unnecessary stress levels of many expecting mothers. Companies participating in this section include:

- Sequenom
- Verinata Health
- Ariosa Diagnostics
- Natera
- Silicon Biosystems

Other areas discussed in this report include preeclampsia and preterm labor. Preeclampsia is a common condition in women and often isn’t detected until later in pregnancy. It can lead to preterm labor, which may be fatal for both the fetus and the mother. So far, a test to screen for the likelihood of preeclampsia does not exist. Detecting the risk of preeclampsia early in pregnancy can allow the expecting mother to take necessary action to avoid preterm labor at all costs, decreasing any complications that may severely affect the fetus including death. Companies highlighted in this section include:

- Metabolomic Diagnostics
- NX PharmaGen

Report Highlights:

- Company goals, customer feedback, challenges encountered, competitive advantage, platform pricing, and future endeavors
- An exclusive Insight Pharma Reports survey specifically highlighting organizational background, areas of research, challenges encountered, and applications in development
- Clinical trial and pipeline data on over 120 products
- Over 130 Company Profiles

Exclusive interviews with:

- Vardit Ravitsky, PhD Associate Professor, Bioethics Programs, School of Public Health, University of Montreal
- Tom Musci, Chief Medical Officer of Ariosa Diagnostics
- Richard Rava, Vice President, Research and Development of Verinata
- Solomon Moshkevich, Vice-President, Marketing and Business Development of Natera
- Robert Proulx, President & GM U.S. Operations of Silicon Biosystems
- Charles Garvey, Chief Executive Officer of Metabolomic Diagnostics
- Dr. Alan Ezrin and Brian Brohman, Co-Founder, Chief Executive Officer of NX PharmaGen; Chief Business Officer of NX PharmaGen
- William Welch; Dirk van den Boom; and Allan Bombard, President and Chief Operating Officer of Sequenom; Executive Vice President, Research & Development and Chief Technology Officer of Sequenom; Chief Medical Officer of Sequenom

Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Ariosa Diagnostics
  • Bioethics Programs
  • Metabolomic Diagnostics
  • Natera
  • NX PharmaGen
  • Sequenom
  • MORE
Executive Summary

Part I: Prenatal Applications

Chapter 1: Invasive Testing
- Karyotyping
- Microarray analysis
- Chapter 2: Noninvasive Testing
- Sequence-based cell-free DNA testing
- Fetal cell isolation

Part II: Noninvasive Prenatal Applications

Chapter 3: Sequenom
- Company background
- Areas of Research
- MaterniT21™ PLUS
- MaterniT21 PLUS validation
- Competitive advantage
- Future endeavors
- Interview with William Welch; Dirk van den Boom; and Allan Bombard
- Company background
- Technologies in development
- SEQureDx platform
- MaterniT21 platform
- Validation techniques
- Areas of improvement
- Competitive advantage
- Customer feedback
- Future endeavors

Chapter 4: Verinata Health
- Company background
- The verifi® prenatal test
- Challenges encountered
- Clinical validation and reimbursement
- Customer feedback
- Interview with Richard Rava
- Company background
- verifi® prenatal test
- Challenges encountered
- Competitive advantage

Chapter 5: Ariosa Diagnostics
- Company background
- Harmony Prenatal Test
- Competitive advantage
- Future endeavors
- Interview with Tom Musci
- Company background
- Harmony Test
- Competitive advantage
- Future endeavors

Chapter 6: Natera
- Company background
- Panorama
- Platform improvements
- Validation
- Challenges encountered
- Competitive advantage
- Future endeavors
- Interview with Solomon Moshkevich
- Company background
- Panorama
- Platform improvements
- Validation
- Challenges encountered
- Customer feedback
- Competitive advantage
- Future endeavors

Chapter 7: Silicon Biosystems
- Company background
- DEPArray System
- Challenges encountered
- Competitive advantage
- Future endeavors
- Interview with Robert Proulx
- Company background
- DEPArray Platform
- Challenges encountered
- Customer feedback
- Future endeavors

Chapter 8: Noninvasive Screening Test Specifications

Part III: Prenatal Complications

Chapter 9: Prenatal Complications
- Preeclampsia
- Preterm labor

Chapter 10: Metabolomic Diagnostics
- Company background
- Preeclampsia screening test
- Competitive advantage
- Future endeavors
- Interview with Charles Garvey
- Company background
- Areas of research
- Competitive advantage
- Future endeavors

Chapter 11: NX PharmaGen
- Company background
- NeXosome platform
- Competitive advantage
- Future endeavors

Interview questions with Dr. Alan Ezrin and Brian Brohman

- Company background
- Preterm labor assays
- Challenges encountered
- Competitive advantage
- Future endeavors

Part IV: Demographic Survey

Chapter 12: Survey Results
- Survey demographics
- Areas of research
- Challenges encountered
- Applications being used for prenatal diagnostics
- Competitive strategies
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
- Ariosa Diagnostics
- Bioethics Programs
- Metabolomic Diagnostics
- NX PharmaGen
- Natera
- Sequenom
- Silicon Biosystems
- Verinata

Note: Product cover images may vary from those shown
Adroll
adroll